Open dataset · Generic Drug Price Cliff · doi:10.5281/zenodo.24182324

Generic Drug Price Cliff 2013-2026: the open dataset behind the Generic Price Cliff

Two years after the first generic approval, the median product's acquisition cost is 80% of its first observed price; after five years 46%; after ten 22%. The spread is wide: after ten years the middle half of products runs from 5% to 53%. A pattern in matched products, not a causal estimate. Version 1.0, published 13 November 2026. Every figure is reproducible from the files below; try it on your own case in the Generic Price Cliff.
Median acquisition cost as a share of the first observed price, by years since the first generic approval

Two years after

80%

Five years after

46%

Ten years after

22%

What is in it?

200 generic tablet and capsule products matched to a single-ingredient Orange Book group with a dated first brand and first generic approval from 2013 to 2022, each with its year-end acquisition cost indexed to its first observed year-end price at or after the first generic approval, and the curve across them by years since that approval.

How should it be read?

NADAC is what retail pharmacies pay to acquire a drug, not a retail price. The first observed year-end price can already reflect generic entry. Matching is by name and form kind, not strength. About 2 percent of the products considered are eligible, so the curve describes a minority of drugs.

What are the files?

The files are hosted on Zenodo with the DOI. Each has a SHA-256 hash, so a downloaded copy can be checked against it.

FileSizeSHA-256 (first 16)
README.md2 KBbd918425c12c29c4
curve.csv419 bytese42cbf3d103ba98b
product-paths.csv110 KBb5e6004166c1cd88
dropped-products.csv172 bytes53a625d4ab9eac73
data.json2 KB9e80306821840d51
control-result.json359 bytese443cd1ad7c06653
PROTOCOL-GENERIC-CLIFF-2026-11-12.md5 KBe59f5eeba2426530
protocol.sha256103 bytesdf2ae034d1886c93
protocol.original.sha256103 bytesbf8aa14951161f2d
code.zip22 KBa3e7fb2e244bd873
SHA256SUMS.txt1019 bytes

How was it checked?

The method was frozen before any figure was published, on 12 November 2026; its SHA-256 hash begins e59f5eeba2426530. A separate reader recomputed figures from the raw files: a random sample recomputed, 0 mismatches. Read how the Generic Price Cliff was checked, including what the check found and what it does not cover.

What is not claimed?

That the first generic caused a price fall; that any drug will follow the curve; anything about retail prices, copays or patient costs.

Has it been corrected?

Amendment 1 (2026-11-12, before publication): the first matching let a single-ingredient capsule match a three-drug combination group; matching now requires a single-ingredient group and exactly one of tablet or capsule in the form. Control: 200 products and 14 curve years, 0 mismatches.

How do I cite it?

Couey, V. W. (2026). Generic Drug Price Cliff 2013-2026: How Acquisition Cost Moves After the First Generic Approval, 200 Drugs (Version 1.0) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.24182324

Cite all versions: doi:10.5281/zenodo.24182323. This version: doi:10.5281/zenodo.24182324.

Where does the data come from?

CMS National Average Drug Acquisition Cost yearly datasets (data.medicaid.gov) and FDA Orange Book data files, read 2026-11-12. Compiled by Vincent Wesley Couey (ORCID 0009-0005-6869-308X). Tool: https://rxgrab.com/tools/generic-price-cliff

Questions about this dataset

What is in the Generic Drug Price Cliff dataset?

200 generic tablet and capsule products matched to a single-ingredient Orange Book group with a dated first brand and first generic approval from 2013 to 2022, each with its year-end acquisition cost indexed to its first observed year-end price at or after the first generic approval, and the curve across them by years since that approval.

Can I reuse it?

Yes. The compilation is licensed CC BY 4.0: reuse it with credit, citing the DOI (10.5281/zenodo.24182324). The underlying records keep the terms of their public source.

How was it checked?

The method was frozen and hashed before any figure was published (12 November 2026), and a separate reader recomputed figures from the raw files: a random sample recomputed, 0 mismatches. The full account is on the how-we-check page for the tool.

What does it not claim?

That the first generic caused a price fall; that any drug will follow the curve; anything about retail prices, copays or patient costs.

Compiled by Vincent Wesley Couey (ORCID 0009-0005-6869-308X).